Insecticides (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
INSECTICID · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Insecticides (India) Limited reported FY25 standalone revenue of ₹2,00,227 lacs, up ~1.8% YoY, while profit after tax jumped ~36.2% to ₹13,977 lacs, pushing EPS to ₹47.61 from ₹34.67. Q4 standalone revenue grew a stronger ~31.8% YoY to ₹35,915 lacs with PAT surging ~73.6% to ₹1,402 lacs, driven by lower raw material costs and operating leverage. Consolidated PAT rose ~39.1% to ₹14,202 lacs, though FY24 consolidated numbers were restated to include the newly acquired Kaeros Research (common control transaction). The board set the 28th AGM for August 12, 2025, appointed a new Secretarial Auditor for 5 years, and noted that auditors (S S Kothari Mehta & Co. LLP and Devesh Parekh & Co.) gave an unmodified (clean) opinion on the results. Operating cash flow nearly halved to ~₹9,462 lacs (standalone) and ₹9,346 lacs (consolidated), partly because the company spent ~₹6,188 lacs on its buyback completed in September 2024.
Profit growth significantly outpaced revenue growth, signalling healthy margin expansion and cost control — supportive for shareholders. However, weak operating cash generation and the ₹5,000 lacs buyback outflow are worth monitoring, and the modest top-line growth tempers the overall positive earnings story.